Comorbid conditions and outcomes in patients with pulmonary arterial hypertension: a REVEAL registry analysis.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Chest

• Publication date

  2013-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1378/chest.11-3241PMID 23348820
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The REVEAL Registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension.

  2012cited by this paper
• Portopulmonary hypertension: a report from the US-based REVEAL Registry.

  2012cited by this paper
• Diagnosis of pulmonary hypertension in the congenital heart disease adult population impact on outcomes.

  2011cited by this paper
• Comparison of body habitus in patients with pulmonary arterial hypertension enrolled in the Registry to Evaluate Early and Long-term PAH Disease Management with normative values from the National Health and Nutrition Examination Survey.

  2011cited by this paper
• Comparison of Body Habitus in Patients With Pulmonary Arterial Hypertension Enrolled in the Registry to Evaluate Early and Long-term PAH Disease Management With Normative Values From the National Health and Nutrition Examination Survey

  2011cited by this paper
• The obesity paradox in elderly obese patients undergoing coronary artery bypass surgery.

  2011cited by this paper
• Paradoxical longevity in obese patients with intracerebral hemorrhage

  2011cited by this paper
• Association Between Obesity and Mortality After Acute First-Ever Stroke: The Obesity–Stroke Paradox

  2011cited by this paper
• The influence of comorbidities on overall survival among older women diagnosed with breast cancer.

  2011cited by this paper
• Association of comorbidities with overall survival in myelodysplastic syndrome: development of a prognostic model.

  2011cited by this paper
• Assessment of endpoints in pulmonary arterial hypertension associated with connective tissue disease

  2010cited by this paper
• Efficacy of standard rehabilitation in COPD outpatients with comorbidities

  2010cited by this paper
• Comorbidity, Hospitalization, and Mortality in COPD: Results from a Longitudinal Study

  2010cited by this paper
• Updated clinical classification of pulmonary hypertension.

  2009cited by this paper
• Pulmonale Hypertonie bei COPD und interstitiellen Lungenerkrankungen

  2009cited by this paper
• Updated clinical classification of pulmonary hypertension.

  2009cited by this paper
• Diagnosis and assessment of pulmonary arterial hypertension.

  2009cited by this paper
• Survival in Portopulmonary Hypertension: Mayo Clinic Experience Categorized by Treatment Subgroups

  2008cited by this paper
• Design of the REVEAL registry for US patients with pulmonary arterial hypertension.

  2008cited by this paper
• Portopulmonary hypertension: survival and prognostic factors.

  2008cited by this paper
• Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines.

  2004cited by this paper
• Comorbidity in patients with rheumatoid arthritis: effect on health-related quality of life.

  2004cited by this paper
• Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults--The Evidence Report. National Institutes of Health.

  1998cited by this paper

• Rab26 promotes hypoxia-induced hyperproliferation of PASMCs by modulating the AT1R-STAT3-YAP axis

  2025cites this paper
• The Impact of Body Mass Index on Survival and Clinical Outcomes in Pulmonary Arterial Hypertension: Revisiting the Obesity Paradox

  2025influential citation
• Frailty in Pulmonary Hypertension: Establishing the Frailty Index and Impact on Survival.

  2025cites this paper
• Significance of Pulmonary Vascular Dysfunction in Chronic Obstructive Pulmonary Disease

  2025cites this paper
• Inflammation and Obesity Correlate in Pulmonary Hypertension but Associate with Diverging Outcomes.

  2025cites this paper
• Pulmonary arterial hypertension with cardiopulmonary comorbidities: is it a unique phenotype?

  2025cites this paper
• Association of Pulmonary Artery Compliance and Adverse Cardiac Events

  2025cites this paper
• Comorbidity Burden in Chronic Thromboembolic Pulmonary Hypertension: Implications and Outcome

  2025cites this paper
• Characteristics, Prognosis and ESC/ERS Risk Stratification in Obese Patients with Pulmonary Arterial Hypertension (PAH).

  2025cites this paper
• Initial therapy in patients with pulmonary arterial hypertension and cardiovascular comorbidities

  2025cites this paper
• Cytochrome P450 1A1 influences obesity-induced pulmonary hypertension.

  2025cites this paper
• Association of Pulmonary Artery Compliance and Adverse Cardiac Events

  2025cites this paper
• Disproportionate impairment in diffusing capacity predicts pulmonary hypertension with an elevated pulmonary vascular resistance in COPD

  2025cites this paper
• Prognostic role of haemodynamics at follow-up in patients with pulmonary arterial hypertension: a challenge to current European Society of Cardiology/European Respiratory Society risk tools

  2024cites this paper
• Predictors of early mortality after lung transplantation for idiopathic pulmonary arterial hypertension

  2024cites this paper
• Left Heart Disease Phenotype in Pulmonary Arterial Hypertension: Considerations for Therapy.

  2024cites this paper
• Obstructive Sleep Apnea, Obesity Hypoventilation Syndrome, and Pulmonary Hypertension: A State-of-the-Art Review.

  2024cites this paper
• Pulmonary hypertension and metabolic disorders

  2024cites this paper
• Epicardial Adipose Tissue as an Independent Risk Factor for Mortality in Pulmonary Arterial Hypertension

  2024cites this paper
• Relationships Among the EmPHasis-10 Questionnaire, the Simplified Four-Strata Risk Assessment Tool, and Echocardiographic Parameters in Patients with Precapillary Pulmonary Hypertension

  2024cites this paper
• Impact of diabetes mellitus on mortality in pulmonary hypertension: A systematic review and meta-analysis

  2024cites this paper
• Controlling Nutritional Status Score Predicts 1-Year Outcomes in Chronic Thromboembolic Pulmonary Hypertension

  2024cites this paper
• Impact of selexipag maintenance dose on persistence, adherence, and hospitalization in US patients with pulmonary arterial hypertension

  2024cites this paper
• Evaluation of patients with severe pulmonary hypertension and a range of comorbidities prescribed inhaled treprostinil

  2024cites this paper
• Viewing Pulmonary Arterial Hypertension Pathogenesis and Opportunities for Disease-Modifying Therapy Through the Lens of Biomass

  2024cites this paper
• Pulmonary Hypertension and Hyperglycemia—Not a Sweet Combination

  2024cites this paper
• Extrapulmonary manifestations of pulmonary arterial hypertension

  2024cites this paper
• The Impact of Cardiovascular and Lung Comorbidities in Patients with Pulmonary Arterial Hypertension: A Systematic Review and Meta-analysis.

  2024cites this paper
• Exploratory and confirmatory factor analysis of emPHasis‐10: The health‐related quality‐of‐life measure in pulmonary hypertension

  2024cites this paper
• Association of non-insulin-based insulin resistance indices with disease severity and adverse outcome in idiopathic pulmonary arterial hypertension: a multi-center cohort study

  2024cites this paper
• Implications of Mean Pulmonary Arterial Wedge Pressure Trajectories in Pulmonary Arterial Hypertension.

  2023cites this paper
• Premorbid weight in pulmonary arterial hypertension

  2023cites this paper
• Healthcare resource utilization in patients with pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD): a real-world data analysis

  2023cites this paper
• Clinical features and long-term survival in idiopathic pulmonary arterial hypertension with thyroid dysfunction: insights from a national multicentre prospective study

  2023influential citation
• Effect of Obesity on Mortality in Pulmonary Hypertension—A Systematic Review and Meta-Analysis

  2023influential citation
• Impact of malnutrition on prognosis in patients with pulmonary arterial hypertension

  2023cites this paper
• Prevalence and prognosis of hypothyroidism in patients with chronic thromboembolic pulmonary hypertension: an updated review with description of case series.

  2023cites this paper
• Management of Pulmonary Hypertension Associated with Chronic Lung Disease

  2023cites this paper
• 2023 Taiwan Society of Cardiology (TSOC) and Taiwan College of Rheumatology (TCR) Joint Consensus on Connective Tissue Disease-Associated Pulmonary Arterial Hypertension.

  2023cites this paper
• Performance of risk stratification scores and role of comorbidities in older vs younger patients with pulmonary arterial hypertension.

  2023cites this paper
• Using health administrative data to identify patients with pulmonary hypertension: A single center, proof of concept validation study in Ontario, Canada

  2022cites this paper
• Increased biventricular hemodynamic forces in precapillary pulmonary hypertension

  2022cites this paper
• Smoking history and pulmonary arterial hypertension: Demographics, onset, and outcomes.

  2022cites this paper
• Medication use by US patients with pulmonary hypertension associated with chronic obstructive pulmonary disease: a retrospective study of administrative data

  2022cites this paper
• Development and evaluation of a predictive algorithm for unsatisfactory response among patients with pulmonary arterial hypertension using health insurance claims data

  2022cites this paper
• Pulmonary hypertension in patients with interstitial lung disease: a tool for early detection

  2022cites this paper
• A pilot study to examine association of BMI with functional class and 6 min walk distance in idiopathic and heritable PAH: Possible association with estrogen metabolism

  2022cites this paper
• The evolution of survival of pulmonary arterial hypertension over 15 years

  2022cites this paper
• Interest of TAPSE/sPAP ratio for noninvasive pulmonary arterial hypertension risk assessment.

  2022cites this paper
• Plasma Cell-Free DNA Predicts Survival and Maps Specific Sources of Injury in Pulmonary Arterial Hypertension

  2022cites this paper
• Association Between Body Mass Index and 30-Day Mortality in Patients with Pulmonary Hypertension Undergoing Non-cardiothoracic, Non-obstetric Surgery

  2022cites this paper
• The Association of Body Mass Index With Mortality Among Pulmonary Hypertension Patients: A Systematic Review and Meta-Analysis of Cohort Studies

  2022cites this paper
• BMI and Treatment Response in Patients With Pulmonary Arterial Hypertension

  2022cites this paper
• Future perspective in diabetic patients with pre- and post-capillary pulmonary hypertension

  2022cites this paper
• Pulmonary Vascular Disease as a Systemic and Multisystem Disease.

  2021cites this paper
• Obesity in Pulmonary Arterial Hypertension

  2021cites this paper
• 2020 Clinical practice guidelines for Pulmonary hypertension, including chronic thromboembolic pulmonary hypertension

  2021cites this paper
• Association of nutritional status and mortality risk in patients with primary pulmonary hypertension

  2021cites this paper
• The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON study

  2021cites this paper
• What’s new in pulmonary hypertension clinical research: lessons from the best abstracts at the 2020 American Thoracic Society International Conference

  2021cites this paper
• Adipokines and Metabolic Regulators in Human and Experimental Pulmonary Arterial Hypertension

  2021cites this paper
• Effect of Obesity on Mortality in Pulmonary Hypertension, Does Obesity Paradox Exist?

  2021cites this paper
• The association between sleep-related breathing disorders and pre-capillary pulmonary hypertension: A chicken and egg question.

  2021cites this paper
• Incidence and prognostic significance of pleural effusions in pulmonary arterial hypertension

  2021cites this paper
• High-fat diet attenuates the improvement of hypoxia-induced pulmonary hypertension in mice during reoxygenation

  2021cites this paper
• Differenzialdiagnostik der pulmonalen Hypertonie am Beispiel der Kollagenose assoziierten PAH im Kontext chronischer Lungen- und Linksherzerkrankungen

  2021cites this paper
• Group 3 Pulmonary Hypertension: A Review of Diagnostics and Clinical Trials.

  2021cites this paper
• Position statement from the Canadian Thoracic Society (CTS) on clinical triage thresholds in respiratory disease patients in the event of a major surge during the COVID-19 pandemic

  2020influential citation
• Test-retest reliability and validity of the timed up and go test and 30-second sit to stand test in patients with pulmonary hypertension.

  2020cites this paper
• Systemic Consequences of Pulmonary Hypertension and Right-Sided Heart Failure

  2020cites this paper
• National trends and inpatient outcomes of pulmonary arterial hypertension related hospitalizations - Analysis of the National Inpatient Sample Database.

  2020cites this paper
• Influence of Body Weight and Diabetes Mellitus in Patients With Pulmonary Hypertension.

  2020cites this paper
• Implementation of a systematic comprehensive geriatric assessment for elderly patients suspected of pulmonary hypertension.

  2020cites this paper
• Obesity, estrogens and adipose tissue dysfunction – implications for pulmonary arterial hypertension

  2020cites this paper
• Obesity in Pulmonary Arterial Hypertension (PAH): The Pulmonary Hypertension Association Registry (PHAR).

  2020cites this paper
• Group 3 pulmonary hypertension: Challenges and opportunities

  2020cites this paper
• Comparative effectiveness of endothelin receptor antagonists on mortality in patients with pulmonary arterial hypertension in a US Medicare population: a retrospective database analysis

  2020cites this paper
• Relative incidence and predictors of pulmonary arterial hypertension complicating type 2 diabetes: The Fremantle Diabetes Study Phase I.

  2020cites this paper
• Pulmonary hypertension in patients with sarcoidosis: A single-center experience

  2020cites this paper
• The myth of the stable pulmonary arterial hypertension patient.

  2019cites this paper
• Baseline history of patients using selexipag for pulmonary arterial hypertension

  2019cites this paper
• Higher plasma fibroblast growth factor 23 levels are associated with a higher risk profile in pulmonary arterial hypertension

  2019cites this paper
• The burden of comorbidities in pulmonary arterial hypertension

  2019influential citation
• Pulmonary Circulation in Obesity, Diabetes, and Metabolic Syndrome.

  2019cites this paper
• Outcomes After Noncardiac Surgery for Patients with Pulmonary Hypertension: A Historical Cohort Study.

  2019cites this paper
• Pulmonary Hypertension and Obesity: Focus on Adiponectin

  2019cites this paper
• The obesity paradox in pulmonary arterial hypertension: the Scottish perspective

  2019cites this paper
• Anticoagulation in pulmonary arterial hypertension: a decision analysis

  2019cites this paper
• Pulmonary hypertension in chronic lung disease and hypoxia

  2019cites this paper
• Pulmonary arterial hypertension populations of special interest: portopulmonary hypertension and pulmonary arterial hypertension associated with congenital heart disease

  2019cites this paper
• Clinical implications of idiopathic pulmonary arterial hypertension phenotypes defined by cluster analysis.

  2019cites this paper
• Diabetic lung disease: fact or fiction?

  2019cites this paper
• Postoperative pulmonary complications in contemporary cohort of patients with pulmonary hypertension.

  2019cites this paper
• Pulmonary Hypertension Associated with Connective Tissue Disease

  2019cites this paper
• Counting Steps: A New Way to Monitor Patients with Pulmonary Arterial Hypertension

  2019cites this paper
• Retrospective observational analysis of hospital discharge database to characterize primary pulmonary hypertension and its outcomes in Spain from 2004 to 2015

  2019cites this paper
• Treatment patterns, healthcare resource utilization, and healthcare costs among patients with pulmonary arterial hypertension in a real-world US database

  2018cites this paper
• Rivaroxaban and macitentan can be coadministered without dose adjustment but the combination of rivaroxaban and St John's wort should be avoided

  2018cites this paper
• Pulmonary vascular dysfunction in metabolic syndrome

  2018influential citation
• Impact of age and comorbidity on risk stratification in idiopathic pulmonary arterial hypertension

  2018cites this paper